Professor, Hematology and Medical Oncology, Emory University School of Medicine
Oncology
Dr. Suresh S. Ramalingam, MD
|
|
Give Review
Suresh Ramalingam practices Oncology. He graduated from Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63/85 in Research/PrimaryCare. Doctor Suresh S. Ramalingam, MD has written publications. He has 101 publications published with PubMed. The lastest publication is: 'Scientific Advances in Lung Cancer 2015.' He accepts all Medicare patients.
Publications
- Adjuvant therapy for nonsmall cell lung Cancer: recent advances and future perspectives.
- Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal...
- Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
- Targeting EGFR in lung Cancer: Lessons learned and future perspectives.
- Plasma biomarker signature associated with improved survival in advanced non-small cell lung Cancer patients on linifanib.
- Development Of A Patient-Reported Outcome (Pro) Assessment Of Core Non-Small Cell Lung Cancer (Nsclc) Symptoms.
- Predictors and outcomes of venous thromboembolism in hospitalized lung Cancer patients: A Nationwide Inpatient Sample database analysis.
- Time to divest from tobacco-funded research.
- GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress Cancer cell growth.
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung Cancer (CheckMate 063):...
- Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung Cancer (NSCLC) p...
- Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database Analysis.
- Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung Cancer.
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
- Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBr...
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell Carcinoma of the head and neck.
- Necitumumab: a new therapeutic option for squamous cell lung Cancer?
- The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung Cancer.
- Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitax...
- Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung...
- Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the Nationa...
- Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American S...
- Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a Systematic review.
- Second-Generation ALK Inhibitors: Filling the Non "MET" Gap.
- Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung Cancer (SCLC): an Eastern Cooperative Oncology Group study...
- ALK-positive non-small cell lung Cancer: Mechanisms of resistance and emerging treatment options.
- Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
- Heat shock protein 90 inhibitors in non-small-cell lung Cancer.
- Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer.
- Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck Cancer.
- Chemoprevention of head and neck Cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
- HPV-associated lung Cancers: an international pooled analysis.
- Advances in the Diagnosis and Treatment of Non-Small Cell Lung Cancer.
- Bcl2 induces DNA replication stress by inhibiting ribonucleotide reDuctase.
- E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung Cancer.
- Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer.
- Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer.
- Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Tri...
- Effect of prophylactic cranial irradiation on survival in elderly patients with limited-stage small cell lung Cancer.
- Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck.
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer.
- CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC.
- A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid Cancer.
- Hsp90 inhibitors.
- c-Myc suppression of DNA double-strand break repair.
- Clinical practice guidelines for Cancer care: utilization and expectations of the practicing oncologist.
- The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung Cancer in vitro and in vivo.
- A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung Cancer.
- Hypogonadism related to crizotinib therapy: Implications for patient care.
- Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung Cancer.
- Acridine yellow G blocks glioblastoma growth via dual inhibition of EGFR and PKC kinases.
- A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid Cancers: a ...
- Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung Cancer data.
- Histone deacetylase inhibitors.
- Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Sma...
- Augmentation of NVP-BEZ235's antiCancer activity against human lung Cancer cells by blockage of autophagy.
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Human immunodeficiency virus-associated lung Cancer in the era of highly active antiretroviral therapy.
- Retinoic acid enhances TRAIL induced apoptosis in Cancer cells by upregulating TRAIL receptor 1 expression.
- Cetuximab for the Treatment of Advanced Bronchioloalveolar Carcinoma (BAC): An Eastern Cooperative Oncology Group Phase II Study (ECOG 1504).
- Lung Cancer: New biological insights and recent therapeutic advances.
- Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
- A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protec...
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic AntiCancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo.
- Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung Cancer.
- Lung Cancer in the elderly: what's age got to do with it?
- Lung Cancer in HIV-positive patients.
- Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell Lung c...
- A phase 1 study of BMS-275183, a novel oral Analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
- Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung Cancer (National Ca...
- Maintenance therapy for advanced non-small cell lung Cancer: current status, controversies, and emerging consensus.
- Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advan...
- Phase 2 study of irinotecan and paclitaxel in patients with recurrent or refractory small cell lung Cancer.
- Antiangiogenic agents in the treatment of nonsmall cell lung Cancer: reality and hope.
- Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung Cancer cells.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- Gender-associated differences in lung Cancer: clinical characteristics and treatment outcomes in women.
- Maintenance therapy in nonsmall-cell lung Cancer: a new treatment paradigm.
- PI3 kinase, mTOR, and AKT pathways.
- Preoperative therapy for early-stage NSCLC: opportunities and challenges.
- Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human Cancer tissues.
- Duration of chemotherapy for metastatic non-small-cell lung Cancer: more may be better after all.
- The role of cetuximab in the management of non-small-cell lung Cancer.
- The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung Cancer.
- Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung Cancer therapy.
- Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced Malignant pleural mesothelioma.
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' antiCancer efficacy.
- Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung Cancer: a multicenter phase 2 study.
- Recent advances in the treatment of Malignant pleural mesothelioma.
- A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
- Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung Cancer: exploring divergent results.
- Targeted therapy for the treatment of non-small cell lung Cancer: focus on inhibition of epidermal growth factor receptor.
- Lung Cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
- Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
- Scientific Advances in Lung Cancer 2015.
Schools
Kilpauk Medical College Tamil Nadu Dr Mgr Medical University
Wayne State University
University Of Pittsburgh
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
Wayne State University School of Medicine -
Kilpauk Medical College
Hospital
-
Emory University Hospital -
Grady Memorial Hospital -
Emory University Hospital Midtown
Drug Facts
| NPI NUMBER | 1457326936 | |
| NPPES Provider LastName | RAMALINGAM | |
| NPPES Provider FirstName | SURESH | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 506.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 86.0 | |
| Percent Opioid Claims | 17.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457326936 |
| Last Name Of The Provider | RAMALINGAM |
| First Name Of The Provider | SURESH |
| View All |
Similar Doctors
|
|
Dr. Wayne B. Harris, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ross M. Michels, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica L. Dreger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amelia B. Zelnak, MD
This Doctor is OpenDoctor Recommended.
|